O-2694
From Wikipedia, the free encyclopedia
Systematic (IUPAC) name | |
---|---|
[(6aR,10aR)-6,6,9-trimethyl-3-(2-methyl-7-morpholin-4-yl-7-oxoheptan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-yl] 4-(di(propan-2-yl)amino)butanoate | |
Clinical data | |
Legal status | ? |
Identifiers | |
ATC code | ? |
PubChem | CID 11714280 |
Chemical data | |
Formula | C38H60N2O5 |
Mol. mass | 624.891 g/mol |
SMILES
| |
(what is this?) (verify) | |
O-2694 is a drug that is a cannabinoid derivative. It has analgesic effects and is used in scientific research. Unlike most cannabinoids discovered to date, it is highly water-soluble, which gives it considerable advantages over many related drugs. It has high affinity for both CB1 and CB2 receptors, with Ki values of 3.7nM at CB1 and 2.8nM at CB2. However, it has complex pharmacokinetics as most of the administered dose is metabolised by hydrolysis of the ester link to the water-insoluble compound O-2372, thus producing a biphasic effects profile that is less suitable for research purposes than the related compound O-2545.[1]
See also
References
- ↑ Martin BR, et al. Pharmacological characterization of novel water-soluble cannabinoids. Journal of Pharmacology and Experimental Therapeutics. 2006 Sep;318(3):1230-9. PMID 16757541
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.